Belgian UCB reports 19% Y/Y revenue growth in Q1 2015.
April 30 (SeeNews) - Belgian biopharmaceuticals firmA UCBA (EBR:UCB) said Thursday its revenue rose by 19% year-on-year to EUR 895 million (USD 1bn) in the first quarter of 2015 due to increased sales of its core medicines treating neurological or immunological diseases.
At constant currency rates, revenue growth was 11%.
Cimzia, Vimpat and Neupro generated combined net sales of EUR 433 million, while anti-epilepticA drugA Keppra reached EUR 190 million. The four drugs together represented 70% of UCB's revenue in the first quarter of 2015.A
UCB expects the continued growth of itsA blockbusters to drive overall company growth. Revenue in 2015 is expected to reach EUR 3.55 billion to EUR 3.65 billion, while recurring earnings before interest, tax, depreciation and amortisation (EBITDA) should increase to about EUR 710-740 million. Core earnings per share (EPS) are seen ranging from EUR 1.90 to EUR 2.05.
(EUR 1.0 = USD 1.110)
|Printer friendly Cite/link Email Feedback|
|Article Type:||Financial report|
|Date:||Apr 30, 2015|
|Previous Article:||State bank Belfius draws buyer interest - report.|
|Next Article:||Belgian energy supplier Eandis looking for new partner - report.|